Depletion of the CD11b+Ly-6C+ cells via administration of an anti-GR-1 Ab resulted in reduced development of demyelinating disease and enhanced virus-specific CD4+ and CD8+ T cell responses (97). The gene discussed is CD4; the disease is demyelinating disease.